This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
McKesson ideaShare 2025 will take place this week in Nashville, Tennessee, and will include educational sessions, keynote sessions, networking events, and hands-on activities. McKesson ideaShare 2025. This year’s conference is taking place from July 10 to 13 in Nashville, Tennessee. REFERENCE McKesson.
This schedule also helped dictate insurance coverage of those recommended vaccines. Drug Topics: How do ACIP recommendations affect broader aspects of vaccine access and utilization, such as insurance reimbursement or public health programs?
Despite a high prevalence of childhood and youth-aged obesity, the use of medications for treating obesity is persistently low among children and young adults (YA), according to an abstract presented at the American Diabetes Association’s 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025. Accessed June 25, 2025.
She warned that changes in vaccine recommendations could impact insurance coverage, patient access, and ultimately public health, particularly for vulnerable populations like low-income children.
Published July 7, 2025 Amy Baxter Staff Reporter post share post print email license stock via Getty Images Listen to the article 6 min This audio is auto-generated. “As Insurance complications As more information emerges about real-world outcomes for GLP-1s, insurers are paying close attention.
From prior authorizations to insurance roadblocks, each decision a pharmacy makes can either ease or complicate that experience. Whether it's trying to check out at a crowded store or navigating complex prescription issues, barriers frustrate people—and pharmacies are no different.
The study investigators included patients who developed AF between January 1, 2010, and December 31, 2018, and were included in the National Health Insurance Service of South Korea. Published 2025 Jun 7. 1 Investigators included a total of 195,195 patients with AD, who had a mean age of 64.4 years and 57.5% Cardiovasc Diabetol.
Read on to learn when to expect a generic for Mounjaro , the difference between compounded tirzepatide and a true generic, and how to save on Mounjaro until a generic version becomes available. What’s the difference between Mounjaro and compounded tirzepatide? So, why is compounded tirzepatide even available? mg per week.
Many people with a Mounjaro prescription look to health insurance, Medicaid , or Medicare to help lower their out-of-pocket costs. Insurance often does come through if the prescription is for diabetes management, not weight loss. However, insurance coverage depends on the insurance company and plan. Others don’t.
While health insurance plans do not always provide coverage of Zepbound for weight loss, coverage may be more likely if the drug is prescribed for sleep apnea. Many insurance plans often do not cover weight loss medications in general,” says Luis Vinas , a board-certified plastic surgeon at Palm Beach Gynecomastia Center.
They look at the list and they prioritize who they want to take on and who they don't want to take on based on their insurance plan and their drugs. That's dependent upon their insurance plan and the medications they use. I am hearing that some independents are just creating a wait list. That is a real problem.
Investigators find that current practices among pharmacists are not fully in alignment with American Diabetes Association (ADA) guideline recommendations for glucagon use, with frequently identified barriers including cost, patient health literacy, and insurance coverage. of patients on a short-acting insulin and 2.3%
Aside from disparities in HbA1c and overall CGM use, researchers uncovered inequities in CGM wear time and access, according to an abstract presented at the American Diabetes Association’s 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025. Among those with T1D, at least 40% are using CGMs.
Robert Barrie June 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Compounded GLP-1RA medication has become a key revenue driver for Hims & Hers’ telehealth platform. Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug.
1 GLP-1 Use Increased Significantly Among Pediatric Patients With T2D in Past 5 Years | ADA 2025 / Edugrafo - stock.adobe.com In recent years, type 2 diabetes has become increasingly common among adolescents in the United States.
Mifepristone Reduces HbA1c in Patients With T2D, Hypercortisolism | ADA 2025 / Carl - stock.adobe.com Data from CATALYST ( NCT05772169 ) showed that mifepristone met its primary endpoint of reduction in HbA1c compared to placebo at 24 weeks. Accessed June 26, 2025. June 23, 2025. Accessed June 26, 2025. May 30, 2025.
These closures, compounded by the decline of independent pharmacies, create a critical gap in care. True visibility comes from layering pharmacy locations on top of geospatial data, such as population density, income levels, transportation access, insurance coverage, and health burden.
PBM headaches will still be around in 2025. Let’s talk about how to make 2025 the year you rise above PBM headaches and take back control of your pharmacy. Target Niche Markets: Consider serving markets like compounding or functional medicine. Get your guide to making them just a wee bit better. The good news?
s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. On June 9, 2025, Secretary of Health and Human Services Robert F. June 9, 2025.
Robert Barrie June 12, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The pact is a significant moment for Novo Nordisk, pouring significant resources into research that is not centred around incretins. Struggles at the drugmaker culminated in long-time CEO Lars Fruergaard Jørgensen stepping down in May 2025.
June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The funds will support clinical milestones along with AI-driven development across Juvenescence’s portfolio. The acquisition forms a key part of Juvenescence’s partnership with the Abu Dhabi global healthcare company M42, which was announced in April 2025.
Obesity-related mortality continued to rise following the COVID-19 pandemic, despite rates expected to stabilize during this time, according to an abstract presented at the American Diabetes Association’s 85th Scientific Sessions, held in Chicago, Illinois, from June 20-23, 2025. Accessed June 24, 2025. With at least 2.8 2022.780872.
Abigail Beaney June 18, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Anne Cathrine Fleischer, vice president of Global Obesity Consumer Engagement and New Business Models at Novo Nordisk, announced the platform at HLTH Europe. Give your business an edge with our leading industry insights.
June 19, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Draig Therapeutics founders: L-R: John Atack, Ruth McKernan and Simon Ward. These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options. Credit: Draig Therapeutics/ GlobeNewswire.
Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. Better customer experience.
Although 5G is currently limited to large cities in developed countries, by around 2025, we can expect its reach will extend beyond the urban areas. Let’s explore how this technology impacts insurance companies, healthcare providers (HCPs), pharma content , and pharmaceutical brands. HCPs The pandemic exposed many flaws in healthcare.
Goldman and Isaacs emphasize the importance of identifying at-risk patients through various health care touchpoints, including doctor's offices and pharmacies, and advocate for routine glucagon prescription and insurance coverage. But I also think everyone should have a ready-to-use cover on their insurance.
Successful RCM implementation can help pharmacies recover significant funds, with Outcomes reporting nearly $3 million recovered for clients in 2024 and 2025.
That means that pharmacists in the twilight of their career have, at some point, filled a prescription, engaged in drug utilization review, filed insurance claims, and counseled per the Omnibus Budget Reconciliation Act of 1990 regulations for many of the products now found in front of the counter. Accessed May 5, 2025. November 2022.
Sayer primarily focuses on barriers to insurance coverage and the need for educational efforts among health care providers and patients. People want products reimbursed, and they're much more likely to use a product if it's paid for by the insurance system. That'll all be fully implemented by the end of 2025.
They highlighted that only 4% of the 15 million people using insulin have a glucagon prescription, largely due to misconceptions about ease of use, cost, and insurance coverage. My insurance isn't going to cover it, and so people don't even try to prescribe it. Subscribe Now!
Leveraging Washington State's progressive pharmacist scope, which allows direct billing to Medicaid and commercial insurances, the program demonstrated the potential of integrating clinical pharmacists into primary care settings.
The medication is available in both brand-name and compounded forms, although the compounded forms are not FDA approved. Compounded semaglutide is made by special compounding pharmacies rather than pharmaceutical companies. A monthly supply of semaglutide ranges from about $129$1,850 without insurance.
There are also compounded versions of tirzepatide and semaglutide, but they are not approved by the Food and Drug Administration (FDA). In fact, the FDA has directed American compounding pharmacies to stop producing these products. Below, find out more about how much they cost, whether they tend to be covered by insurance, and more.
Drug Topics: How do ACIP recommendations affect broader aspects of vaccine access and utilization, such as insurance reimbursement or public health programs? Cleveland: So I'll start as a provider. So I think it's going to limit access.
Getting this passed would mean broadening coverage within CMS, and then, hopefully, private insurers would follow suit. CMS leads the way when it comes to new therapies and approval, so hopefully, this means broadening access to both private and government-based insurers.
Ross Law July 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The global oncology market is set to grow at a compound annual growth rate (CAGR) of 24.5%. Image credit: CI Photos / Shutterstock. Give your business an edge with our leading industry insights. Login Registration is disabled.
Utilization of HER2 therapies is positively associated with private insurance, academic facility treatment, and recent diagnosis years. Disparities in HER2 therapy access are linked to rural treatment, Black race, Medicare insurance, and older age. 3 Among the patients, approximately 75.8% in 2013 to 80.9%
Patients with inflammatory conditions achieved similar clinical outcomes after switching from the reference adalimumab (Humira; AbbVie) to a biosimilar, according to real-world data presented at the 2025 American Society of Health-System Pharmacists Pharmacy Futures Meeting. Accessed June 26, 2025. June 12, 2025. June 7–11.
Semi-synthetic opioids are scientifically modified versions of these naturally occurring compounds. American Psychiatric Association , 2025) Men are more likely to use and become dependent on opioids, but women are prescribed opioids more often than men. The post Opioid statistics, 2025 appeared first on The Checkup.
June 30, 2025) – The National Community Pharmacists Association today issued a statement on behalf of CEO B. PCMA unanimous Supreme Court decision in 2020, which allowed states to regulate PBMs, the big health insurance companies and their PBM lobby have been barnstorming the country putting up one legal challenge after another.
You also look at sometimes the unfortunate situation of the patient's insurance, for example, no longer covering the medication, whether it's an insurance formulary change or, for example, a patient switches insurances due to a job change. We on our own help to navigate patients through that process as well.
Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to customers. Compounded semaglutide is a personalised weight loss medicine, which is chemically identical to branded alternatives.
June 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Bird’s-eye view of the current Vetter site in Des Plaines where the clinical manufacturing facility will be built. The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content